Cadrenal Therapeutics, Inc. Common Stock (CVKD)
CVKD Stock Price Chart
Explore Cadrenal Therapeutics, Inc. Common Stock interactive price chart. Choose custom timeframes to analyze CVKD price movements and trends.
CVKD Company Profile
Discover essential business fundamentals and corporate details for Cadrenal Therapeutics, Inc. Common Stock (CVKD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Jan 2023
Employees
5.00
Website
https://www.cadrenal.comCEO
Quang X. Pham
Description
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
CVKD Financial Timeline
Browse a chronological timeline of Cadrenal Therapeutics, Inc. Common Stock corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$1.55.
Earnings released on 7 May 2026
EPS came in at -$1.04 surpassing the estimated -$1.51 by +31.13%.
Earnings released on 31 Mar 2026
EPS came in at -$1.41 falling short of the estimated -$1.17 by -20.51%.
Earnings released on 10 Nov 2025
EPS came in at -$1.31 surpassing the estimated -$1.55 by +15.48%.
Earnings released on 11 Aug 2025
EPS came in at -$1.87 falling short of the estimated -$1.60 by -16.88%.
Earnings released on 8 May 2025
EPS came in at -$2.09 falling short of the estimated -$1.64 by -27.44%.
Earnings released on 13 Mar 2025
EPS came in at -$2.74 falling short of the estimated -$1.71 by -60.23%, while revenue for the quarter reached $2.13k .
Earnings released on 7 Nov 2024
EPS came in at -$2.18 falling short of the estimated -$1.83 by -19.13%.
Stock split effective on 20 Aug 2024
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 Aug 2024
EPS came in at -$2.25 surpassing the estimated -$19.04 by +88.18%.
Earnings released on 9 May 2024
EPS came in at -$1.50 falling short of the estimated -$1.05 by -42.86%.
Earnings released on 11 Mar 2024
EPS came in at -$0.75 surpassing the estimated -$1.35 by +44.44%, while revenue for the quarter reached $2.77k .
Earnings released on 9 Nov 2023
EPS came in at -$1.05 matching the estimated -$1.05.
Earnings released on 10 Aug 2023
EPS came in at -$1.35 .
Earnings released on 10 May 2023
EPS came in at -$0.41 .
Earnings released on 30 Mar 2023
EPS came in at -$6.46 .
Earnings released on 30 Sept 2022
EPS came in at -$0.09 .
Earnings released on 30 Jun 2022
EPS came in at -$0.04 .
Earnings released on 31 Mar 2022
EPS came in at -$0.02 .
CVKD Stock Performance
Access detailed CVKD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
